- Breast Cancer Over 70: How Much Treatment Is Enough?
- AHA News: Pandemic-Fueled Drug Abuse Threatens Hearts, Lives
- AHA News: After Two Heart Valve Surgeries, a Mental Toll
- Every American Adult Now Eligible for COVID-19 Vaccine
- Health Highlights, April 20, 2021
- New Hope Against a Rare but Incurable Eye Cancer
- Too Much Red Meat Might Harm Your Heart
- Sleepwalking Tied to Higher Odds for Parkinson’s in Men
- Lots of Teens, Young Adults Are Helping to Care for Older Loved Ones
- ‘Double-Masking’ It? Proper Fit Is Crucial, Study Finds
Antiviral Combination Approved for Hepatitis C

Viekira Pak, a combination of four antiviral drugs — ombitasvir, paritaprevir, ritonavir and dasabuvir — has been approved by the U.S. Food and Drug Administration to treat hepatitis C infection, including a major complication, cirrhosis of the liver.
Some 3.2 million Americans are infected with the viral disease, which can lead to complications including reduced liver function, liver failure or liver cancer, the FDA said in a news release. Most infected people have no symptoms before onset of liver damage.
Without proper treatment, 15 percent to 30 percent will develop advanced liver disease known as cirrhosis, the agency said.
The combination pack’s safety and effectiveness were evaluated in clinical studies involving more than 2,300 people with chronic hepatitis C, with and without cirrhosis. The most common side effects included fatigue, itching, weakness, lack of energy, nausea and trouble sleeping.
Viekira Pak is marketed by AbbVie Inc., based in North Chicago.
More information
Visit the FDA to learn more.
Source: HealthDay